Institut Pierre Louis d'Epidémiologie et de Santé Publique IPLESP, Sorbonne Université, INSERM, Paris, France.
Department of Neurology, University Hospital of Heidelberg, Heidelberg, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Lancet Neurol. 2018 Apr;17(4):327-334. doi: 10.1016/S1474-4422(18)30042-5. Epub 2018 Mar 13.
Spinocerebellar ataxias are dominantly inherited progressive ataxia disorders that can lead to premature death. We aimed to study the overall survival of patients with the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6) and to identify the strongest contributing predictors that affect survival.
In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, from 17 ataxia referral centres in ten European countries; participants had positive genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias. Survival was defined as the time from enrolment to death for any reason. We used the Cox regression model adjusted for age at baseline to analyse survival. We used prognostic factors with a p value less than 0·05 from a multivariate model to build nomograms and assessed their performance based on discrimination and calibration. The EUROSCA study is registered with ClinicalTrials.gov, number NCT02440763.
Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1 (n=117), SCA2 (n=162), SCA3 (n=139), or SCA6 (n=107) were enrolled and followed up. The 10-year survival rate was 57% (95% CI 47-69) for SCA1, 74% (67-81) for SCA2, 73% (65-82) for SCA3, and 87% (80-94) for SCA6. Factors associated with shorter survival were: dysphagia (hazard ratio 4·52, 95% CI 1·83-11·15) and a higher value for the Scale for the Assessment and Rating of Ataxia (SARA) score (1·26, 1·19-1·33) for patients with SCA1; older age at inclusion (1·04, 1·01-1·08), longer CAG repeat length (1·16, 1·03-1·31), and higher SARA score (1·15, 1·10-1·20) for patients with SCA2; older age at inclusion (1·44, 1·20-1·74), dystonia (2·65, 1·21-5·53), higher SARA score (1·26, 1·17-1·35), and negative interaction between CAG and age at inclusion (0·994, 0·991-0·997) for patients with SCA3; and higher SARA score (1·17, 1·08-1·27) for patients with SCA6. The nomogram-predicted probability of 10-year survival showed good discrimination (c index 0·905 [SD 0·027] for SCA1, 0·822 [0·032] for SCA2, 0·891 [0·021] for SCA3, and 0·825 [0·054] for SCA6).
Our study provides quantitative data on the survival of patients with the most common spinocerebellar ataxias, based on a long follow-up period. These results have implications for the design of future interventional studies of spinocerebellar ataxias; for example, the prognostic survival nomogram could be useful for selection and stratification of patients. Our findings need validation in an external population before they can be used to counsel patients and their families.
European Union 6th Framework programme, German Ministry of Education and Research, Polish Ministry of Scientific Research and Information Technology, European Union 7th Framework programme, and Fondation pour la Recherche Médicale.
脊髓小脑共济失调是一种显性遗传性进行性共济失调疾病,可导致过早死亡。我们旨在研究最常见的脊髓小脑共济失调(SCA1、SCA2、SCA3 和 SCA6)患者的总体生存率,并确定影响生存的最强预测因素。
在这项欧洲脊髓小脑共济失调研究(EUROSCA)中,我们招募了来自 10 个欧洲国家的 17 个共济失调转诊中心的 18 岁及以上的男性和女性;参与者具有 SCA1、SCA2、SCA3 或 SCA6 的阳性基因检测结果和进行性、其他原因不明的共济失调。生存定义为从入组到任何原因死亡的时间。我们使用 Cox 回归模型调整了基线时的年龄来分析生存。我们使用多变量模型中 p 值小于 0.05 的预后因素来构建列线图,并根据区分度和校准度评估其性能。EUROSCA 研究在 ClinicalTrials.gov 上注册,编号为 NCT02440763。
在 2005 年 7 月 1 日至 2006 年 8 月 31 日期间,我们招募了 525 名 SCA1(n=117)、SCA2(n=162)、SCA3(n=139)或 SCA6(n=107)患者,并进行了随访。SCA1 的 10 年生存率为 57%(95%CI 47-69),SCA2 为 74%(67-81),SCA3 为 73%(65-82),SCA6 为 87%(80-94)。与生存率较短相关的因素包括:吞咽困难(危险比 4.52,95%CI 1.83-11.15)和 SCA1 患者的共济失调评估和评分量表(SARA)评分较高(1.26,1.19-1.33);年龄较大(1.04,1.01-1.08)、CAG 重复长度较长(1.16,1.03-1.31)和 SARA 评分较高(1.15,1.10-1.20);年龄较大(1.44,1.20-1.74)、肌张力障碍(2.65,1.21-5.53)、SARA 评分较高(1.26,1.17-1.35)和 CAG 与年龄的负交互作用(0.994,0.991-0.997);SCA3 患者 SARA 评分较高(1.17,1.08-1.27)。列线图预测的 10 年生存率显示出良好的区分度(SCA1 的 c 指数为 0.905 [0.027],SCA2 为 0.822 [0.032],SCA3 为 0.891 [0.021],SCA6 为 0.825 [0.054])。
我们的研究提供了基于长期随访的最常见脊髓小脑共济失调患者生存的定量数据。这些结果对脊髓小脑共济失调的未来干预研究设计具有重要意义;例如,预后生存列线图可用于选择和分层患者。在将其用于指导患者及其家属之前,我们需要在外部人群中验证这些发现。
欧盟第六框架计划、德国教育和研究部、波兰科学研究和信息技术部、欧盟第七框架计划以及法国医学研究基金会。